Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Files An 8-K Submission of Matters to a Vote of Security Holders
Submission of Matters to a Vote of Security
At the Portola Pharmaceuticals, Inc. (the Company) 2017 annual
meeting of stockholders held on June16, 2017, the stockholders
voted on the three proposals listed below. The proposals are
described in detail in the Companys definitive proxy statement
for the 2017 annual meeting, filed with the Securities and
Exchange Commission on April24, 2017 (the Proxy Statement). The
results of the matters voted upon at the meeting were:
Each of the Class I nominees of the Companys Board of
Directors were elected to hold office until the Companys 2020
annual meeting of stockholders. The Class I nominees were:
Jeffrey W. Bird, M.D., Ph.D.; 41,600,519 shares of Common
Stock voted for, 1,122,304 withheld, and 8,383,657 broker
non-votes; John H. Johnson; 38,697,578 shares of Common Stock
voted for, 4,025,245 withheld, and 8,383,657 broker
non-votes; and H. Ward Wolff; 41,613,515 shares of Common
Stock voted for, 1,109,308 withheld, and 8,383,657 broker
non-votes. The terms of office of Class II directors Dennis
Fenton, Ph.D., Charles J. Homcy, M.D. and David Stump, M.D.
continue until the Companys 2018 annual meeting of
stockholders. The terms of office of Class III directors
Laura Brege, Hollings C. Renton and William Lis continue
until the Companys 2019 annual meeting of stockholders.
The stockholders approved, on a non-binding, advisory basis,
of the compensation of the Companys named executive officers
as disclosed in the Proxy Statement: 41,927,755 shares of
Common Stock voted for, 595,667 against, 199,401 abstaining,
and 8,383,657 broker non-votes.
The stockholders ratified the selection by the Audit
Committee of the Companys Board of Directors of Ernst Young
LLP as the independent registered public accounting firm of
the Company for its fiscal year ending December31, 2017:
50,702,428 shares of Common Stock voted for, 293,308 against,
110,744 abstaining, and 0 broker non-votes.
About Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.